Solicitation, total small business set-aside, first published as presolicitation
National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2025
75N91024R00013
National Institutes of Health, NIH NCI. Research and Development in the Physical, Engineering, and Life Sciences.
Awarded
$299,991.00 obligated so far on USAspending
Description
As published on SAM.gov.
The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.
Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. For this solicitation rare cancers with a 5-year survival rate of less than 50 % are encouraged and rare cancers would be defined as including all the cancers listed by the NIH Genetics and Rare Diseases Information Center. The list can be found here: https://rarediseases.info.nih.gov/search-result?category=Cancer.
Access the NCI Surveillance, Epidemiology, and End Results Program (SEER) database (https://seer.cancer.gov/) for more information regarding 5-year cancer survival rates. Preliminary data is not required; however, the ideas should have sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path.
Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurship skills and to develop or refine a business model and commercialization plan.
This solicitation is a Concept Award program that could serve as a pipeline for the federal Small Business Innovation Research (SBIR) program. Background for the SBIR program can be found in the Small Business Administration’s policy directive found here: https://www.sbir.gov/sites/default/files/SBA%20SBIR_STTR_POLICY_DIRECTIVE_May2023.pdf
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- Recipient
- Aso Therapeutics, Inc.
- UEI
- K8R9YHMX6Q31
- CAGE
- 06A12
- Vendor location
- San Rafael, CA
- Contract
- 75N91025C00011, definitive contract
- Obligated
- $299,991.00
- Actions
- 2 between September 15, 2025 and September 11, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 55 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- FY2025 SBIR Concept Clearance Award or Topic Development of Therapeutic or Preventative Technologies for Treatment or Prevention of Pediatric Cancers And/Or Rare Cancers
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
- Recipient
- Tenaci-T Therapeutics LLC
- UEI
- MTRTYVL8N717
- CAGE
- 01U66
- Vendor location
- Missouri City, TX
- Contract
- 75N91025C00012, definitive contract
- Obligated
- $297,621.00
- Actions
- 2 between September 16, 2025 and September 14, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 55 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- FY2025 SBIR Concept Clearance Award for Topic Development of Therapeutic or Preventative Technologies for Treatment or Prevention of Pediatric Cancers And/Or Rare Cancers.
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
- Recipient
- Pathcision Medicine, Inc.
- UEI
- CK6QRF2GLBT1
- CAGE
- 9BD69
- Vendor location
- Watertown, MA
- Contract
- 75N91025C00018, definitive contract
- Obligated
- $299,981.00
- Actions
- 2 between August 5, 2025 and July 20, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 55 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- SBIR Concept Award for a Novel Delivery Approach to Transform Metastatic Pancreatic Cancer Treatment and Prevention
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
- Recipient
- Cloverleaf Bio, Inc.
- UEI
- NR4GYWZ66HM5
- CAGE
- 0QEA6
- Vendor location
- New Haven, CT
- Contract
- 75N91025C00020, definitive contract
- Obligated
- $300,000.00
- Actions
- 2 between September 10, 2025 and September 9, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 55 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- SBIR FY25 Concept Award: Development of Engineered Trna Therapeutics for Clear Cell Renal Cell Carcinoma
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
- Recipient
- Tippingpoint Biosciences, Inc.
- UEI
- SECRMGV8SX87
- CAGE
- 9C7V7
- Vendor location
- Los Altos, CA
- Contract
- 75N91025C00021, definitive contract
- Obligated
- $300,000.00
- Actions
- 2 between September 11, 2025 and September 1, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 52 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- SBIR FY25 Concept Award: Targeting Dysfunctional Chromatin Networks in Dipg
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
- Recipient
- Merlin Biotech Inc.
- UEI
- U33SZN8R3966
- CAGE
- 9K6A1
- Vendor location
- Doylestown, PA
- Contract
- 75N91025C00025, definitive contract
- Obligated
- $300,000.00
- Actions
- 2 between September 16, 2025 and August 20, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 55 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- SBIR FY25 Concept Award, Development of an Immunotherapy for Ewing Sarcoma Using a Novel Murine Model
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
- Recipient
- Syzonc, Inc.
- UEI
- JRJ6JNJ2CHF3
- CAGE
- 9GXP6
- Vendor location
- Ewing, NJ
- Contract
- 75N91025C00027, definitive contract
- Obligated
- $299,878.00
- Actions
- 3 between September 25, 2025 and September 9, 2026
- Competition
- Full and Open Competition After Exclusion of Sources, 55 offers received
- Set-aside reported
- Small Business Set Aside - Total
- Described as
- SBIR FY25 Concept Award, Targeting Plod2 in Undifferentiated Pleomorphic Sarcoma
- Match
- solicitation number 75N91024R00013 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
Points of contact
- Tanya Renwickncioasbir@mail.nih.gov
Also open from this buyer
- NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAMSolicitationSmall businessNAICS 5417175N98026R00109Closes in 3 daysSep 21